Sacituzumab tirumotecan
Sacituzumab tirumotecan 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Breast Neoplasms、Triple Negative Breast Neoplasms、HR Low-Positive/HER2-Negative Breast Neoplasms。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
5 项
已进入 III/IV 期
29 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Merck Sharp & Dohme LLC
- Zhejiang Provincial People's Hospital
- Guangdong Association of Clinical Trials
- Fudan University
- Shanghai Chest Hospital
- Tufts Medical Center
- The First Affiliated Hospital of Xiamen University
- Sun Yat-sen University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Brazil、Chile、中国、Czechia、法国、德国、意大利、日本、挪威、Singapore、South Korea
正在招募患者的 Sacituzumab tirumotecan 研究
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
I 期 / II 期招募中美国BrazilChile中国NCT06780111Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
不适用招募中中国NCT07068542A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
II 期招募中中国NCT07375316Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
II 期招募中中国NCT07471776Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
II 期招募中中国NCT07811752Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
II 期招募中美国NCT07718854Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
II 期招募中中国NCT06992739Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
II 期招募中中国NCT07258108A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
III 期招募中美国Argentina澳大利亚奥地利NCT06952504A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
I 期 / II 期招募中美国BrazilChile中国NCT07286149Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
II 期招募中中国NCT07179783A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
III 期招募中美国Argentina澳大利亚比利时NCT06841354Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
III 期招募中美国Argentina澳大利亚BrazilNCT06170788A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
I 期 / II 期招募中美国澳大利亚加拿大ChileNCT06428409Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
I 期 / II 期招募中美国BrazilChile中国NCT06469944A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer
II 期招募中中国NCT07850791SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study
II 期招募中中国NCT07670013A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
III 期招募中美国Argentina澳大利亚奥地利NCT07318558Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
II 期招募中中国NCT07623577Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
III 期招募中美国Argentina奥地利BrazilNCT06422143SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
II 期招募中中国NCT07256236A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)
II 期招募中美国中国香港瑞士NCT07785609A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
I 期 / II 期招募中美国BrazilChile中国NCT05319730SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
II 期招募中中国NCT07697586
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。